Expertises
Immunologie et virologie
- Professeur agrégé
Centre Armand-Frappier Santé Biotechnologie
531, boulevard des Prairies
Laval (Québec) H7V 1B7
CANADA
Intérêts de recherche
Bien que les traitements antirétroviraux actuels permettent de survivre à l’infection au VIH-1, ils sont néanmoins associés avec une multitude d’effets secondaires indésirables. De plus, les traitements antirétroviraux restent inefficaces pour éliminer complètement le virus de l’organisme, ainsi que l’inflammation résiduelle qui persiste chez ces patients. De ce fait, les patients sous traitements continuent à présenter des perturbations métaboliques et moléculaires, qui participent à un affaiblissement de leur protection immunitaire. Pour pouvoir un jour prétendre à arrêter ces traitements, il faut en premier trouver le moyen d’interférer avec des voies moléculaires afin de renforcer cette protection immunitaire.
Les travaux du professeur Van Grevenynghe et de son équipe de recherche visent à identifier les mécanismes cellulaires responsables de la survie réduite de la mémoire T que l’on retrouve chez les patients infectés. Leur travail inclut également l’étude des élites contrôleurs, un groupe unique de patients infectés au VIH-1 possédant une capacité naturelle à coexister avec le virus. Comprendre les mécanismes responsables d’une telle protection sans intervention médicale est un outil de choix pour mettre au point de nouvelle stratégies thérapeutiques chez les autres groupes de patients.
Le laboratoire du professeur Van Grevenynghe utilise des techniques expérimentales de pointe comme la cytométrie de flux multiparamétriques et Imaging, ainsi que l’analyseur de flux métabolique Seahorse.
Publications
NB. 9 publications including 5 as senior author (since my recruitment in the IAF at mid-February 2015)
2018
Loucif H., Dagenais-Lussier X., Murira A., Stäger S., Tremblay C., and van Grevenynghe J. Deciphering natural control of HIV-1: a valuable strategy to achieve antiretroviral therapy termination. Cytokine and Growth Factor Reviews. 40:90-98. April.
2017
Dagenais-Lussier X., Loucif H., Murira A., Laulhé X., Stäger S., Lamarre A., and van Grevenynghe J. Sustained IFN-I expression during established persistent viral infection : a « bad seed » for protective immunity. Viruses. 10(1). December.
2016
Dagenais-Lussier X., Mouna A., Mehraj V., El-Far M., Tremblay C., Sekaly R.P., Routy J.P., and van Grevenynghe J. Kynurenine reduces memory CD4 T-cell survival by interfering with IL-2 signaling early during HIV-1 infection. Journal of Virology. 90(17):7967-79. August.
El-Far M., Kouassi P., Sylla M., Zhang Y., Fouda A., Fabre T., Goulet J.P., van GrevenyngheJ., et al. Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected slow progressors.Science Reports. 6:22902. March.
Aounallah M., Dagenais-Lussier X., El-Far M., Mehraj V., Jenabian M.A., Routy J.P., and van Grevenynghe J. Current topics in HIV pathogenesis, part 2: Inflammation drives a Warburg-like effect on the metabolism of HIV-infected subjects.Cytokine and Growth Factor Reviews. 28:1-10. April.
2015
Cubas R.A., van Grevenynghe J., et al. Reversible reprogramming of memory Tfh cell function during chronic HIV infection. Journal of Immunology.195(12):5625-36. December.
Dagenais-Lussier X., Aounallah M., Routy J.P., Tremblay C., Sekaly R.P., El-Far M., and van Grevenynghe J. Current topics in HIV-1 pathogenesis: The emergence of deregulated immuno-metabolism in HIV-infected subjects.Cytokine and Growth Factor Reviews. 26(6):603-13. December.
Metcalf T.U., Cubas R.A., Ghneim K., Cartwright M.J., van GrevenyngheJ., et al. Global analyses revealed age-related alterations in innate immune responses after stimulation of pathogen recognition receptors.Aging Cell. 14(3):421-32. June.
El-Far M., Ancuta P., Routy J.P., Zhang Y., Bakeman W., Bordi R., DaFonseca S., Said E.A., Gosselin A., Tep T.S., Eichbaum Q., van Grevenynghe J., et al. Nef promotes evasion of human immunodeficiency virus type 1-infected cells from the CTLA-4-mediated inhibition of T-cell activation.J. Gen. Virol. 96(Pt 6):1463-77. June.
2014
Olagnier D., Sze A., Bel Hadj S., Chiang C., Steel C.,Lin R., Hiscott J., and van Grevenynghe J.. HTLV-1 Tax-mediated inhibition of FOXO3a activity is critical for the persistence of terminally differentiated CD4+ T cells. Revision in Plos Pathogens.
Shulak L., Beljanski V., Chiang C., Dutta S., van Grevenynghe J., Belgnaoui S.M., Nguyên T., Di Lenardo T., Semmes J., Lin R., and Hiscott J. Histone deacetylase inhibitors potentiate VSV oncolysis in prostate cancer cells by modulating NF-kB signalling. Journal of Virology. 88(5): 2927-40.
2013
Shulak L., Beljanski V., Chiang C., Dutta S., van Grevenynghe J., Belgnaoui S.M., Nguyên T., Di Lenardo T., Semmes J., Lin R., and Hiscott J. Histone deacetylase inhibitors potentiate VSV oncolysis in prostate cancer cells by modulating NF-kB signalling. Journal of Virology. 88(5): 2927-40.
SzeA., OlagnierD., LinR., van Grevenynghe J. and Hiscott J. SAMHD1 Host Restriction Factor: A Link with Innate Immune Sensing onf Rtrovirus Infection.Journal of Molecular Biology. 425(24):4981-94.
Sze A., Belgnaoui S.M., OlagnierD., Lin R., Hiscott J., and van Grevenynghe J.. Host restriction factor SAMHD1 limits human T-cell leukemia virus type 1 infection of monocytes via the innate immune sensor STING. Cell Host and Microbe. 14(4): 422-34.
Benyebdri F., van Grevenynghe J., Tang V., Goulet M-L., wu J., Stojdl D., Hiscott J. and Lin R. Triptolide mediated-inhibition of interferon signalling enhances vesicular stomatitis virus based oncolysis. Molecular Therapy.21(11): 2043-53.
Samuel S., Beljanski V., van Grevenynghe J., Richards S., Ben Yebdri F., He Z., Nichols C., Belgnaoui S.M., Steel C., Goulet M-L., Shamy A., Brown D., Abesada G., Haddad E.K. and Hiscott J. Bcl-2 inhibitors sensitize therapy-resistant chronic lymphocytic leukemia cells to VSV oncolysis. Molecular Therapy. 21(7): 1413-23.
Cubas R.A., Mudd J.C., Savoye A.L., Perreau M., van Grevenynghe J., Metcalf T., Connick E., Meditz A., Freeman G.J., Abesada-Terk G.Jr., Jacobson J.M., Crotty S., Estes J.D., Pantaleo G., Lederman M.M., and Haddad E.K.. Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nature Medicine. 19(4): 494-9.
2012
Trautmann L., Mbitikon-Kobo F-M., Goulet J-P., Peretz Y., Yu Shi, van Grevenynghe J., Procopio F.A., BoulasselM.R., Routy J-P., ChomontN., Haddad E.K.and Sekaly R.P. Profound Metabolic, Functional and Cytolytic Differences Characterize HIV-Specific CD8 T Cells in Primary and Chronic HIV Infection. Blood. 120(17): 3466-77.
van Grevenynghe J., Cubas R.A., Da Fonseca S., Metcalf T., Tremblay C.L., Trautmann L., Sekaly R.P, Schatzle J. and Haddad E.K. Foxo3a: an integrator of immune dysfunction during HIV infection. Cytokine and Growth Factor Reviews. 23(4-5): 245-21.
2011
van Grevenynghe J., Cubas R.A., Noto A., Da Fonseca S., Zhong H., Peretz Y., Filali-Mouhim A., Dupuy F.P., Procopio F.A., Chomont N., Balderas R.S., Said E.A, Boulassel M.R., Tremblay C., Routy J.P., Sekaly R.P and Haddad E.K. Loss of memory B-cells during chronic HIV infection is driven by FOXO3a- and TRAIL-mediated apoptosis. Journal of Clinical Investigation. 121(10): 3877-88. (Selected for highlight in the « In This Issue » section)
2010
Said E.A, Dupuy F.P., Trautmann L., Zhang Y., Shi Y., El-Far M., Hill B.J., Noto A., Ancuta P., Peretz Y., Fonseca S.G., van Grevenynghe J., Boulassel M.R., Bruneau J., Shoukry N.H., Routy J.P., Douek D.C., Haddad E.K.and Sekaly R.P. Programmed death-1 induced interleukin-10 production by monocytes impairs CD4(+) T cell activation during HIV infection. Nature Medicine. 16(4): 452-9.
2008
van Grevenynghe J., Procopio F.A, He Z., Chomont N., Riou C., Zhang Y., Gimmig S., Boucher G., Wilkinson P., Shi Y., Yassine-Diab B., Said E.A., Trautmann L., El Far M., Balderas R.S., Boulassel M.R., Routy J.P., Haddad E.K., and Sekaly R.P. Transcription factor FOXO3a controls the persistence of memory CD4(+) T cells during HIV infection. Nature Medicine. 14(3): 266-74.
van Grevenynghe J., Halwani R., Chomont N., Ancuta P., Peretz Y., Tanel A., Procopio F.A., Shi Y., Said E.A., Haddad E.K.and Sekaly R.P. Lymph node architecture collapse and consequent modulation of FOXO3a pathway on memory T- and B-cells during HIV infection. Seminar in Immunology. 20(3):196-203.
El Far M., Halwani R., Said E.A., Trautmann L., Doroudchi M., Janbazian L., Fonseca S.G., van Grevenynghe J., Yassine-Diab B., Sekaly R.P., and Haddad E.K. T-cell Exhaustion in HIV Infection.Curr HIV/AIDS Rep. 5(1):13-9.
Vernhet L., Morzadec C., van Grevenynghe J., Bareau B., Corolleur M., Fest T., and Fardel O. Inorganic arsenic induces necrosis of human CD34-positive haematopoietic stem cells. Environ. Toxicol. 23(2): 263-8.
2007
Riou C., Yassine-Diab B., van Grevenynghe J., Somogyi R., Greller L.D., Gagnon D., Gimmig S., Wilkinson P., Shi Y., Cameron M.J., Campos-Gonzales R., Balderas R.S., Kelvin D., Sekaly R.P., and Haddad E.K.Convergence of TCR and cytokine signaling leads to FOXO3a phosphorylation and drives the survival of CD4+ central memory T cells. Journal of Experimental Medicine. 204(1): 79-91.
2006
van Grevenynghe J., Monteiro P., Gilot D., Fest T., and Fardel O.
Human endothelial progenitors constitute targets for environmental atherogenic polycyclic aromatic hydrocarbons.
Biochemical and Biophysical research communications. 314(3): 763-9.
Sparfel L., van Grevenynghe J., Le Vee M., Aninat C., and Fardel O.
Potent inhibition of carcinogen-bioactivating cytochrome P450 1B1 by the p53 inhibitor pifithrin {alpha}
Carcinogenesis. 27(3): 656-63.
2005
van grevenynghe J., Monteiro P., Bernard M., Langouet S., Le Berre C., Fest T., and Fardel O.
Human CD34-positive hematopoietic stem cells constitute targets for carcinogenic polycyclic aromatic hydrocarbons.
Journal of Pharmacology and Experimental Therapeutics. 314, 693-702.
2004
van grevenynghe J., Sparfel L., Le Vee M., Gilot D., Drenou B., Fauchet R., and Fardel O.
Cytochrome P450-dependant toxicity of environmental polycyclic aromatic hydrocarbons towards human macrophages.
Biochemical and Biophysical research communications. 317, 708-12.
2003
van grevenynghe J., Rion S., Le Ferrec E., Le Vee M., Amiot L., Fauchet R., and Fardel O.
Polycyclic aromatic hydrocarbons inhibit differentiation